Vaccinex has been granted a patent for a combination therapy involving the administration of pulsed dendritic cells and an immunoregulator molecule inhibitor for the treatment of cancer. The therapy includes intratumoral administration of dendritic cells pulsed with HER2 oncodriver and systemic administration of an immunoregulatory molecule inhibitor that binds specifically to SEMA4D. The therapy has shown promising results in shrinking both injected and non-injected tumors. GlobalData’s report on Vaccinex gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vaccinex, personalized cancer vaccines was a key innovation area identified from patents. Vaccinex's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Combination therapy for cancer using dendritic cells and inhibitor
A recently granted patent (Publication Number: US11660330B2) describes an anti-cancer combination therapy that involves the use of dendritic cells and an immunoregulatory molecule inhibitor. The therapy is formulated for both intratumoral and systemic administration and has shown promising results in shrinking tumors.
The first claim of the patent outlines the combination therapy, which includes dendritic cells pulsed with a human epidermal growth factor receptor 2 (HER2) oncodriver for intratumoral administration, and an immunoregulatory molecule inhibitor that specifically binds to Semaphorin 4D (SEMA4D) for systemic administration. The administration of this combination therapy has been found to result in tumor shrinkage in both injected and non-injected tumors.
Claim 2 specifies that the dendritic cells used in the therapy are activated with interleukin-12 (IL-12) prior to administration. IL-12 is known to have immunostimulatory effects and can enhance the anti-cancer response.
Claim 3 identifies pepinemab as an example of an antagonist antibody that specifically binds to SEMA4D. Pepinemab is a potential candidate for the immunoregulatory molecule inhibitor component of the therapy.
Claim 4 states that the anti-SEMA4D antibody or antigen-binding fragment used in the therapy blocks the binding of SEMA4D to its receptor. This mechanism of action is important for inhibiting the signaling pathway associated with SEMA4D.
Claims 5 and 6 provide specific amino acid sequences for the variable heavy chain (VH) and variable light chain (VL) of the anti-SEMA4D antibody or antigen-binding fragment. These sequences are important for the specificity and binding affinity of the antibody.
Overall, this granted patent describes a novel anti-cancer combination therapy that utilizes dendritic cells and an immunoregulatory molecule inhibitor. The therapy has shown efficacy in shrinking tumors and has the potential to be a valuable addition to the field of cancer treatment. Further research and development are needed to explore the full potential of this therapy and its application in clinical settings.
To know more about GlobalData’s detailed insights on Vaccinex, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
